SFM
CARM

Sphera Funds Management’s Carisma Therapeutics CARM Stock Holding History

Sphera Funds Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,500
Closed -$1.35M – 108
2018
Q3 		$1.35M Sell
31,500
-87,353
-73% -$3.4M 0.16% 91
2018
Q2 		$4.63M Buy
+118,853
New +$5.24M 0.64% 43
2015
Q2 		– Sell
-4,356
Closed -$777K – 138
2015
Q1 		$777K Hold
4,356
– – 0.08% 138
2014
Q4 		$1.03M Buy
+4,356
New +$977K 0.18% 109

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's CARM Position: Q4 2018 in Review

Sphera Funds Management sold out of Carisma Therapeutics (CARM) in Q4 2018, closing a stake of 31,500 shares — an estimated $1.35M sold.

Sphera Funds Management first reported a position in CARM in Q4 2014 and held it in 4 quarters. The position peaked at $4.63M in Q2 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q4 2018.

  • Sphera Funds Management reported no remaining Carisma Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sphera Funds Management sold 31,500 Carisma Therapeutics shares in Q4 2018, an estimated $1.35M.
  • Sphera Funds Management first reported a position in Carisma Therapeutics in Q4 2014 and held it in 4 quarters.
  • Sphera Funds Management's Carisma Therapeutics position peaked at $4.63M in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2018.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.